bullish

Nippon Shinyaku (4516 JP): New Drugs and Rich Pipeline Enhance Conviction on Future Growth

407 Views18 Dec 2021 01:01
SUMMARY
  • By succeeding to launch at least one distinctive product each year, Nippon Shinyaku (4516 JP) increased both revenue and operating profit for nine fiscal years in a row.
  • The company’s new drug Viltepso, targeting 8% of Duchenne muscular dystrophy patient population has an estimated peak sale of more than $400 million.
  • By FY24, the company plans to launch one new in-house drug for myelofibrosis, which is preparing to go for phase 2 trial.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Logo
Rising
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x